Asston Pharmaceuticals Ltd. Hits Upper Circuit on BSE, 27 October 2026

For anyone already holding the stock, the Asston Pharmaceuticals upper circuit on 27 October 2026 was a clean day; for anyone not yet in, it was a locked door. Asston Pharmaceuticals Ltd. (APL) reached Rs 141.16 on BSE, a 5% rise on the previous close of Rs 134.44, and its market cap stood at Rs 146.85 crore.

Buyers met the exchange-defined price band, and the stock was fixed at that ceiling when this was written.

Key Takeaways

• Asston Pharmaceuticals Ltd. (APL) hit the upper circuit on BSE at Rs 141.16 on 27 October 2026.
• The session move was +5% against a previous close of Rs 134.44.
• Market capitalisation stood at Rs 146.85 crore with a PE ratio of 38.
• No official company announcement or verified catalyst was confirmed at the time of writing.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric	Value
Stock	Asston Pharmaceuticals Ltd.
Current Price / LTP	Rs 141.16
Day Move	5%
Previous Close	Rs 134.44
Day Open	Rs 129.99
Day High	Rs 141.16
Day Low	Rs 129.99
Upper Circuit Price	Rs 141.16
Upper Circuit Limit	Rs 141.16
Market Cap	Rs 146.85 crore
Selected Exchange	BSE
PE Ratio	38

All figures above are as of 27 October 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

The day started lower. Asston Pharmaceuticals Ltd. opened at Rs 129.99, below the previous close of Rs 134.44, and that open also proved to be the session low. From there the price climbed steadily to Rs 141.16, the band limit and the day's high.

The net gain was Rs 6.72, or 5%. Every number here is taken from BSE alone, so the open, the range and the ceiling are measured on one consistent basis.

Band limits and previous-close values may differ from one exchange to the next, which is the reason for sticking to a single venue throughout.

Why Asston Pharmaceuticals Ltd. Hit Upper Circuit

Buying interest carried Asston Pharmaceuticals Ltd. up to its price band, and the data stops there. No company announcement or verified external catalyst was on record when this was written, so price action and market sentiment are the only available explanation.

Without a confirmed trigger, the move is not linked to results, a corporate action, sector news or rumours. Should a verified announcement surface, a separate update would carry it.

The highest price of the session was Rs 141.16.

What the Asston Pharmaceuticals Upper Circuit Means

An upper circuit is the top price an exchange permits for a stock within one session, set by its band rules. For Asston Pharmaceuticals Ltd., that ceiling was Rs 141.16 on 27 October 2026.

The mechanism exists to temper sharp swings and keep trading orderly. It describes how the market is structured and does not forecast a return. In this case it marks where the session's buying ran into the band.

Asston Pharmaceuticals Ltd. Fundamentals and Valuation

The wider data adds some context. Asston Pharmaceuticals Ltd. carried a PE ratio of 38 and a PB ratio of 2.22, with book value of Rs 60.43 and EPS of 3.54, against a market cap of Rs 146.85 crore. These are reference figures, not a buy, sell or hold view.

A PB ratio of 2.22 means the shares were priced above reported book value per share. Premiums like that can reflect expectations for growth, the quality of assets, or light trading in a smaller counter.

For a holder, the gain on the day is a price event; for a new buyer, valuation and return ratios are the more relevant questions, and they need their own review.

Peer and Sector Context

Asston Pharmaceuticals Ltd. belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company	Market Cap	PE	PB	ROE
Ind-Swift Laboratories Ltd.	Rs 2986.18 crore	52.09	2.08	3.47%
Advanced Enzyme Technologies Ltd.	Rs 2806.68 crore	16.92	1.69	11.43%
Hikal Ltd.	Rs 2402.52 crore	-	2.02	-3.97%
Fredun Pharmaceuticals Ltd.	Rs 2338.74 crore	53.37	7.67	16.09%
Beta Drugs Ltd.	Rs 2199.67 crore	42.37	5.03	18.78%

A dash in the PE column means no PE ratio was carried for that company in the source data, which happens when reported earnings are negative or have not been refreshed. Those companies are left out of the average below rather than counted as zero.

Several of these peers are far larger by market capitalisation than Asston Pharmaceuticals Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Asston Pharmaceuticals Ltd.'s PE ratio was 38, compared with an available peer PE average of 41.19, calculated from the 4 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical Snapshot

The technical snapshot adds context: RSI was 60.95, the 50-day moving average was 103.65 and the 200-day moving average was 88.83.

What Readers Should Know

One fact is firm: Asston Pharmaceuticals Ltd. reached the upper circuit on BSE at Rs 141.16 on 27 October 2026, a 5% day move.

New buyers face an execution problem. With orders stacked at the band and sellers holding back, the quoted price may not be one at which a fresh order fills. No official catalyst was confirmed either.

An upper circuit is a market update rather than a conclusion. The band signals strong near-term demand, yet business fundamentals, valuation, liquidity, risk and confirmed company disclosures still need checking afterwards.

Frequently Asked Questions

Why did Asston Pharmaceuticals Ltd. hit upper circuit on 27 October 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was APL share price on 27 October 2026?

The last traded price used in this article was Rs 141.16 on BSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for APL?

The upper circuit price was Rs 141.16. The stated exchange upper circuit limit was Rs 141.16. The event numbers in this article are aligned to BSE.

What is Asston Pharmaceuticals Ltd.'s market cap and PE ratio?

Asston Pharmaceuticals Ltd.'s market cap was Rs 146.85 crore. PE ratio was 38.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 27 October 2026.

Does hitting an upper circuit mean Asston Pharmaceuticals Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Asston Pharmaceuticals Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Asston Pharmaceuticals Ltd. the stated limit was Rs 141.16. For this session, Asston Pharmaceuticals Ltd. moved 5%.